Hyderabad is all set to host the 5th edition of ‘iPhex-2017’ for the first time at Hitex Exhibition Center (HITEX) from April 27-29 at Madhapur in the city.
Since its inception in the year 2013, the exclusive Indian pharmaceutical and healthcare exhibition (iPhex) has been giving the biggest international platform for the Indian pharmaceutical and healthcare companies to help explore and build international business networking and there by enhance the Indian pharmaceutical exports.
According to Ravi Uday Bhaskar, Director General of Pharmexcil, this time iPhex-2017 hosted in Hyderabad is going to become the biggest platform and particularly facilitate the SMEs to learn about the international regulations, registration processes and other aspects and help them boost their business. “This time, iPhex-2017 will host more than 600 overseas delegates from 120 courtiers across the globe. Unlike earlier editions, we are planning to give more focusing on manufacturers rather than distributors. The main objective of shifting iPhex from Mumbai to Hyderabad is to showcase alternative destinations of API, Formulations and Healthcare to the world,” says the Director General.
Apart from Mumbai and Ahmadabad, which are leading formulation destination, Hyderabad is also equally growing as an alternative formulation hub. Moreover, the city is also having the advantage of being the leading API manufacturing hub of India. Given this, Pharmexcil, the leading organizer of the event wants to make it a memorable and worthwhile platform for not just the formulators, but also for the API manufacturers and healthcare sector.
Coming to the highlights of this year’s event, organizers are giving priority to Manufacturing, Regulatory and Scientific sessions. In addition to it an exclusive interaction between researchers and industry leaders is being organised to discuss up on new development technologies for large scale, reliable, cost effective and environment friendly API manufacturing in the country.
“In accordance to the government’s policy to propagate ‘make in India’ initiative, Pharmexcil is also facilitating interaction between experts of national research institutes, members of industry leaders, members from bulk drug manufacturing, senior scientists and officials from Indian Institute of Chemical technology to discuss on issues relating to overdependence of API imports and possible solutions to help India self sustain the same. We have already conducted two meetings on the issue and very soon another meeting is being planned to be held on 7th this month,” informed Uday Bhaskar.